In relapsed/refractory myeloma after 1–2 prior lines, iberdomide-daratumumab-dexamethasone raised MRD-negative complete response vs daratumumab-bortezomib-dexamethasone (41% vs 21%; OR 2·8). Grade 3–4 events 92% vs 70%; PFS still pending.
RCTn = 420
Lonial et al. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial